NODAL MARGINAL ZONE B-CELL LYMPHOMA RECURRENT

This adverse event was reported 3 times

These drugs are most commonly taken by patients reporting NODAL MARGINAL ZONE B-CELL LYMPHOMA RECURRENT:

# Drug Count
0 RITUXIMAB 3
1 CYCLOPHOSPHAMIDE 2
2 CYCLOPHOSPHAMIDE FOR INJECTION 2
3 CYCLOPHOSPHAMIDE INJECTION, SOLUTION 2
4 DOXORUBICIN 2
5 CARMUSTINE 1
6 CISPLATIN 1
7 CYTARABINE 1
8 DEXAMETHASONE 1
9 DEXAMETHASONE 1.5 MG 1
See all common drugs associated with NODAL MARGINAL ZONE B-CELL LYMPHOMA RECURRENT

NODAL MARGINAL ZONE B-CELL LYMPHOMA RECURRENT is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 IBRITUMOMAB TIUXETAN 1 0.0007
1 CARMUSTINE 1 0.0002
2 MITOXANTRONE HYDROCHLORIDE 1 0.0002
3 IFOSFAMIDE FOR INJECTION 1 0.0000
4 MELPHALAN HYDROCHLORIDE 1 0.0000
5 DOXORUBICIN 2 0.0000
6 CYTARABINE 1 0.0000
7 FLUCONAZOLE 1 0.0000
8 RITUXIMAB 3 0.0000
9 ETOPOSIDE 1 0.0000
See all drugs enriched for association with NODAL MARGINAL ZONE B-CELL LYMPHOMA RECURRENT

NODAL MARGINAL ZONE B-CELL LYMPHOMA RECURRENT is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Topoisomerase Inhibitor [EPC] 1 0.0000
1 CD20-directed Cytolytic Antibody [EPC] 3 0.0000
2 Alkylating Drug [EPC] 2 0.0000
3 Azole Antifungal [EPC] 1 0.0000
4 Platinum-based Drug [EPC] 1 0.0000
5 Nucleoside Metabolic Inhibitor [EPC] 1 0.0000
6 Corticosteroid [EPC] 2 0.0000
See all drug classes enriched for association with NODAL MARGINAL ZONE B-CELL LYMPHOMA RECURRENT